An updated Alzheimer’s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 6, 2014, Pages 581-598

  Conrado, Daniela J ^a   Denney, William S ^a   Chen, Danny ^a   Ito, Kaori ^a  

^a PFIZER INC   (United States)

Author keywords

ADAS cog; Alzheimer s disease; Coalition Against Major Diseases (CAMD); Disease progression; NONMEM; Patient level model based meta analysis

Indexed keywords

APOLIPOPROTEIN E4; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONTE CARLO METHOD; NONLINEAR REGRESSION ANALYSIS; NONMEM; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK FACTOR; SAMPLE SIZE; STEP WISE MULTIPLE REGRESSION; CLINICAL TRIAL (TOPIC); GENETICS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84911953039     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9375-z     Document Type: Article

References (30)

1. Alzheimer’s Association (2013) 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 9(2). http://www.alz.org/downloads/facts_figures_2013.pdf. Accessed 29 July 2013
2. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 9(7):702–716. doi:10.1016/S1474-4422(10)70119-8
3. Gobburu JV, Lesko LJ (2009) Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49:291–301. doi:10.1146/annurev.pharmtox.011008.145613
4. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141(11):1356–1364
5. Holford NH, Peace KE (1992) Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89(23):11466–11470
6. Holford NH, Peace KE (1992) Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89(23):11471–11475
7. Holford NH, Peace K (1994) The effect of tacrine and lecithin in Alzheimer’s disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol 47(1):17–23
8. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T (2010) Disease progression meta-analysis model in Alzheimer’s disease. Alzheimers Dement 6(1):39–53. doi:10.1016/j.jalz.2009.05.665
9. Ito K, Corrigan B, Zhao Q, French J, Miller R, Soares H, Katz E, Nicholas T, Billing B, Anziano R, Fullerton T (2011) Disease progression model for cognitive deterioration from Alzheimer’s Disease Neuroimaging Initiative database. Alzheimers Dement 7(2):151–160. doi:10.1016/j.jalz.2010.03.018
10. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3(89):89ra57. doi:10.1126/scitranslmed.3002156
11. Yang E, Farnum M, Lobanov V, Schultz T, Verbeeck R, Raghavan N, Samtani MN, Novak G, Narayan V, DiBernardo A, Alzheimer’s Disease Neuroimaging Initiative (2011) Quantifying the pathophysiological timeline of Alzheimer’s disease. J Alzheimers Dis 26(4):745–753. doi:10.3233/JAD-2011-110551
12. Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, Dibernardo A, Narayan V (2012) An improved model for disease progression in patients from the Alzheimer’s disease neuroimaging initiative. J Clin Pharmacol 52(5):629–644. doi:10.1177/0091270011405497
13. Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K, Qiu R, Stephenson D, Gastonguay MR, Corrigan B (2012) Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis. J Pharmacokinet Pharmacodyn 39(5):479–498. doi:10.1007/s10928-012-9263-3
14. Critical Path Institute. Coalition Against Major Diseases database. http://c-path.org/programs/camd/. Accessed 14 Feb 2014
15. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
16. R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/
17. Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2010) Nonlinear Mixed Effects Model Program (NONMEM) version 7.1.2, Icon Development Solutions, Ellicott City, MD, USA. http://www.iconplc.com/technology/products/nonmem
18. Tsoularis A, Wallace J (2002) Analysis of logistic growth models. Math Biosci 179(1):21–55
19. Xu XS, Samtani MN, Dunne A, Nandy P, Vermeulen A, De Ridder F, Alzheimer’s Disease Neuroimaging Initiative (2013) Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries. J Pharmacokinet Pharmacodyn 40(4):537–544. doi:10.1007/s10928-013-9318-0
20. Smithson M, Verkuilen J (2006) A better lemon squeezer? Maximum-likelihood regression with beta-distributed dependent variables. Psychol Methods 11(1):54–71. doi:10.1037/1082-989X.11.1.54
21. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241–257. doi:10.1016/j.cmpb.2005.04.005
22. Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2013) Nonlinear Mixed Effects Model Program (NONMEM) version 7.3.0, Icon Development Solutions, Ellicott City, MD, USA. http://www.iconplc.com/technology/products/nonmem
23. SAGE Publications I Akaike Information Criterion (2007) Encyclopedia of measurement and statistics. SAGE Publications, Inc. SAGE Publications, Inc., Thousand Oaks, CA. doi:10.4135/9781412952644
24. Crean S, Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL, Arrighi HM (2011) Apolipoprotein E epsilon4 prevalence in Alzheimer’s disease patients varies across global populations: a systematic literature review and meta-analysis. Dement Geriatr Cogn Disord 31(1):20–30. doi:10.1159/000321984
25. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ (1997) The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2):S51–S56
26. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106–118. doi:10.1038/nrneurol.2012.263
27. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123):921–923
28. Xu WL, Caracciolo B, Wang HX, Santoni G, Winblad B, Fratiglioni L (2013) Accelerated progression from mild cognitive impairment to dementia among APOE ε4ε4 carriers. J Alzheimers Dis 33(2):507–515. doi:10.3233/JAD-2012-121369
29. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269. doi:10.1016/j.jalz.2011.03.005
30. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, Mittman B (2002) Guidelines for managing Alzheimer’s disease: part II. Treatment. Am Fam Physician 65(12):2525–2534